NICE is unable to make a recommendation on human alpa1-proteinase inhibitor (Respreeza) for treating emphysema in adults. CSL Behring UK has confirmed that it does not intend to launch the product in England and Wales. The reasons for this decision are primarily related to the company’s inability to offer the product at a price to meet the current threshold of cost effectiveness.

The context for this decision is important, and related to the unique, complex and high-cost nature of plasma-derived therapy production.

If the company wishes to make a submission to NICE in the future for this topic it will be rescheduled back into the work programme.

Guidance development process

How we develop NICE technology appraisal guidance